Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy:: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

被引：112

作者：

Sanz, Miguel A. ^{[1
]}

Montesinos, Pau ^{[2
]}

Vellenga, Edo ^{[3
]}

Rayon, Consuelo ^{[4
]}

de la Serna, Javier ^{[5
]}

Parody, Ricardo ^{[6
]}

Bergua, Juan M. ^{[7
]}

Leon, Angel ^{[8
]}

Negri, Silvia ^{[9
]}

Gonzalez, Marcos ^{[10
]}

Rivas, Concha ^{[11
]}

Esteve, Jordi ^{[12
]}

Milone, Gustavo ^{[13
]}

Gonzalez, Jose D. ^{[14
]}

Amutio, Elena ^{[15
]}

Brunet, Salut ^{[16
]}

Garcia-Larana, J. ^{[17
]}

Colomer, Dolors ^{[12
]}

Calasanz, Maria J. ^{[18
]}

Chillon, Carmen ^{[10
]}

Barragan, Eva

Bolufer, Pascual

Lowenberg, Bob ^{[19
]}

机构：

[1] Univ Hosp Fe, Dept Hematol, Valencia 46009, Spain

[2] Univ Autonoma Barcelona, Dept Med, E-08193 Barcelona, Spain

[3] Univ Groningen Hosp, Groningen, Netherlands

[4] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain

[5] Hosp 12 Octubre, E-28041 Madrid, Spain

[6] Hosp Univ Virgen del Rocio, Seville, Spain

[7] Hosp San Pedro Alcantara, Caceres, Spain

[8] Gen Hosp, Jerez de la Frontera, Spain

[9] Hosp Carlos Haya, Malaga, Spain

[10] Univ Hosp, Salamanca, Spain

[11] Gen Hosp, Alicante, Spain

[12] Hosp Clin Barcelona, Barcelona, Spain

[13] Fundaleu, Buenos Aires, DF, Argentina

[14] Hosp Insular, Las Palmas Gran Canaria, Spain

[15] Hosp Cruces, Baracaldo, Spain

[16] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[17] Hosp Ramon & Cajal, E-28034 Madrid, Spain

[18] Univ Navarra, E-31080 Pamplona, Spain

[19] Erasmus Univ, Med Ctr, Rotterdam, Netherlands

来源：

BLOOD | 2008年 / 112卷 / 08期

关键词：

D O I：

10.1182/blood-2008-05-159632

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A previous report of the Programa de Estudio y Tratamiento de las Hemopatias Malignas (PETHEMA) Group showed that a risk-adapted strategy combining all-trans retinoic acid (ATRA) and anthracycline monochemotherapy for induction and consolidation in newly diagnosed acute promyelocytic leukemia results in an improved outcome. Here we analyze treatment outcome of an enlarged series of patients who have been followed up for a median of 65 months. From November 1999 through July 2005 (LPA99 trial), 560 patients received induction therapy with ATRA plus idarubicin. Patients achieving complete remission received 3 courses of consolidation followed by maintenance with ATRA and low-dose chemotherapy. The 5-year cumulative incidence of relapse and disease-free survival were 11% and 84%, respectively. These results compare favorably with those obtained in the previous LPA96 study (P = .019 and P = .04, respectively). This updated analysis confirms the high antileukemic efficacy, low toxicity, and high degree of compliance of a risk-adapted strategy combining ATRA and anthracycline monochemotherapy for consolidation therapy.

引用

页码：3130 / 3134

页数：5

共 13 条

[1]

COX DR, 1972, J R STAT SOC B, V34, P187

[2] Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy [J].

de Botton, S ;

Sanz, MA ;

Chevret, S ;

Dombret, H ;

Martin, G ;

Thomas, X ;

Mediavilla, JD ;

Recher, C ;

Ades, L ;

Quesnel, B ;

Brault, P ;

Fey, M ;

Wandt, H ;

Machover, D ;

Guerci, A ;

Maloisel, F ;

Stoppa, AM ;

Rayon, C ;

Ribera, JM ;

Chomienne, C ;

Degos, L ;

Fenaux, P .

LEUKEMIA, 2006, 20 (01) :35-41

[3] Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin [J].

de la Serna, Javier ;

Montesinos, Pau ;

Vellenga, Edo ;

Rayon, Chelo ;

Parody, Ricardo ;

Leon, Angel ;

Esteve, Jordi ;

Bergua, Juan M. ;

Milone, Gustavo ;

Deben, Guillermo ;

Rivas, Concha ;

Gonzalez, Marcos ;

Tormo, Mar ;

Diaz-Mediavilla, Joaquin ;

Gonzalez, Jose D. ;

Negri, Silvia ;

Amutio, Elena ;

Brunet, Salut ;

Lowenberg, Bob ;

Sanz, Miguel A. .

BLOOD, 2008, 111 (07) :3395-3402

[4] A CLASS OF K-SAMPLE TESTS FOR COMPARING THE CUMULATIVE INCIDENCE OF A COMPETING RISK [J].

GRAY, RJ .

ANNALS OF STATISTICS, 1988, 16 (03) :1141-1154

[5] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].

KAPLAN, EL ;

MEIER, P .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481

[6]

MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163

[7] KAPLAN-MEIER, MARGINAL OR CONDITIONAL-PROBABILITY CURVES IN SUMMARIZING COMPETING RISKS FAILURE TIME DATA [J].

PEPE, MS ;

MORI, M .

STATISTICS IN MEDICINE, 1993, 12 (08) :737-751

[8] Sex differences in prognosis for children with acute lymphoblastic leukemia [J].

Pui, CH ;

Boyett, JM ;

Relling, MV ;

Harrison, PL ;

Rivera, GK ;

Behm, FG ;

Sandlund, JT ;

Ribeiro, RC ;

Rubnitz, JE ;

Gajjar, A ;

Evans, WE .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :818-824

[9]

Sanz MA, 2000, BLOOD, V96, P1247

[10]

Sanz MA, 1999, BLOOD, V94, P3015

← 1 2 →